Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554105 | 1.00 | HCAR2 (0.42) | HCAR2TAAR1ADRA2AADRA2CADRA2B | |
| SCHEMBL104838 | 1.00 | HCAR2 (0.42) | HCAR2TAAR1ADRA2AADRA2CADRA2B | |
| SCHEMBL198133 | 0.89 | HCAR2 (0.45) | HCAR2TAAR1ADRA2AADRA2CADRA2B | |
| Phosphine SCHEMBL20897413 | 0.86 | CYP2D6 (0.46) | HCAR2TAAR1ADRA2AADRA2CADRA2B | |
| SCHEMBL12559730 | 0.86 | ESR1 (0.33) | — | |
| SCHEMBL3163758 | 0.84 | HCAR2 (0.42) | HCAR2TAAR1ADRA2AADRA2CADRA2B | |
| Hydrochloric Acid SCHEMBL28482713 | 0.83 | ALDH1A1 (0.48) | HCAR2TAAR1ADRA2AADRA2CLMNA | |
| SCHEMBL6272307 | 0.82 | HCAR2 (0.46) | HCAR2TAAR1ADRA2AADRA2CADRA2B | |
| SCHEMBL8750423 | 0.82 | PTGS2 (0.43) | HCAR2TAAR1ADRA2AADRA2CADRA2B | |
| SCHEMBL22875947 | 0.80 | TAAR1 (0.40) | HCAR2TAAR1ADRA2AADRA2CADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10000463-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | HCAR2 170/4885TAAR1 49/4885ADRA2A 171/4885 |
| US-10000463-B2 | Halogen-substituted heterocyclic compound | LPAR1, LPAR4, LPAR2 | HCAR2 127/4885TAAR1 121/4885ADRA2A 92/4885 |
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | HCAR2 3656/4885TAAR1 2237/4885ADRA2A 1814/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | HCAR2 3656/4885TAAR1 2237/4885ADRA2A 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.